Detalhe da pesquisa
1.
Resistance to EGFR Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer via Newly Acquired Targetable Oncogenic Driver Alterations With an Emphasis on BRAF: Case Series and Literature Review of Treatment.
JCO Precis Oncol
; 6: e2100551, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35952324